Stroke Prevention in Atrial Fibrillation - View on Upcoming Milestones
DETAILED DATA FROM ARISTOTLE STUDY AT ESC – AUGUST 28th. BMY is likely to announce detailed data on Eliquis in SPAF from the ARISTOTLE study. The data on Eliquis from ARISTOTLE will be compared to the data on Pradaxa from RELY trial and not Xarelto- ROCKET AF, as there are major differences in trial design. The detailed data will be important from an Eliquis approval perspective, but from a competitive positioning perspective, the differentiation vis-à-vis Pradaxa/Xarelto is unlikely to be robust enough to influence clinician’s choice….. FDA Advisory Committee Meeting For Xarelto Approval In SPAF – September 8th- Once Daily dosing is the winning trait On September 8, We expect a unanimous vote in favor of approval and do not expect any hurdles on account of non-inferiority demonstrated in ITT analysis and poor INR control in the ROCKET AF study.
COMPANIES MENTIONED
PFE, BMY, JNJ, BAYER
PFE, BMY, JNJ, BAYER
